

Epilepsy Treatment and Education Task Force

Meeting Minutes/Summary Notes

Tuesday, July 10th, 2012

WELCOME

The meeting was called to order at 3:05 pm on Tuesday, July 10th, 2012, in Room 319 of the Lucas State Office Building in Des Moines, Iowa.

PRESENT

Members of the Task Force present: Chasity Mease, Kevin Harris, Kristin Wells, Brett Barker, Dr. Moore, Dr. Janus, Geoff Wahl and Dr. Friedgood.

There were also several non-members present, including: Jill Myers-Gadelmann, Bradey Wells, Roxanne Cogil and several others.

MINUTES FROM PREVIOUS MEETING

There was a motion to approve the June 12th minutes by Kevin which was 2nd by Chasity

SUMMARY OF DISCUSSION

Overview of Flyers – Kevin

19,000 flyers were printed. All the flyers will go to the Epilepsy Foundation. There is no funding left to mail out the flyers, but it is posted on the Department of Public Health website and will be distributed at Health Fairs, Epilepsy Foundation educational events, Neurology Clinics, Pharmacy locations and other areas throughout the state.

Summary of Epilepsy Task Force Activities at the Iowa Pharmacy Association's Annual Meeting – Chasity

Chasity provided a handout to task force members entitled "Summary of Epilepsy Task Force Activities at the Iowa Pharmacy Association's Annual Meeting", which summarizes the comments from the pharmacists. Chasity spoke at the Iowa Pharmacy Association meeting. 170 pharmacists were in attendance.

Discussion included the IA Code of 155a.32 regarding DAW.

155A.32 DRUG PRODUCT SELECTION -- RESTRICTIONS.

1. If an authorized prescriber prescribes, in writing, electronically, by facsimile, or orally, a drug by its brand or trade name, the pharmacist may exercise professional judgment in the economic interest of the patient by selecting a drug product with the same generic name and demonstrated bioavailability as the one prescribed for dispensing and sale to the patient. If the cost of the prescription or any part of it will be paid by expenditure of public funds authorized under chapter 249A, the pharmacist shall exercise professional judgment by selecting a drug product with the same generic name and demonstrated bioavailability as the one prescribed for dispensing and sale. If the pharmacist exercises drug product selection, the pharmacist shall inform the patient of the savings which the patient will obtain as a result of the drug product selection and pass on to the patient no less than fifty percent of the difference in actual acquisition costs between the drug prescribed and the drug substituted.

2. The pharmacist shall not exercise the drug product selection described in this section if either of the following is true:

a. The prescriber specifically indicates that no drug product

selection shall be made.

b. The person presenting the prescription indicates that only the specific drug product prescribed should be dispensed. However, this paragraph does not apply if the cost of the prescription or any part of it will be paid by expenditure of public funds authorized under chapter 249A.

3. If selection of a generically equivalent product is made under this section, the pharmacist making the selection shall note that fact and the name of the manufacturer of the selected drug on the prescription presented by the patient or the patient's adult representative or transmitted by the prescriber or the prescriber's authorized agent.

Section History: Recent Form

87 Acts, ch 215, § 32; 2004 Acts, ch 1036, §17

Past efforts to pass legislation and what the future holds – Threase

Biggest challenges are that legislation said this isn't a problem. The first legislation had to do with no substitutions on the AED medications. The focus for the second legislation was that there could not be any substitutions, the DAW needed to be recognized due to fragile population to protect health. Any substitution would require approval of the physician. Brett Barker noted that it was broad of legislation. PBMs and Pharmacies were against of the legislation.

The group suggested having someone from Pharmacy Board to come to a Task Force meeting to answer the tough questions regarding DAW and mail orders, formal complaint process. Chasity will contact Board of Pharmacy to get a representative at the next meeting. Submit questions ahead of time by August 9th to chasity.mease@walgreens.com.

It is a patient safety issue. There is a great need for education on this issue. Moving forward would require very specific recommendations, why we would need the legislation why is it necessary, define problem and solution. The group agreed that having all parties around table engaged and in agreement in order to move forward.

ADJOURNMENT

Adjournment by Chasity and seconded by Geoff Wahl and Dr. Moore. Next meeting will be on August 14th at 3:00 p.m. Room 517 in the Lucas Building.